Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP448174.RAaEY0psX6jW3M9_LabJnMKY8K_rvGpun9XMmvTMC-ftg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP448174.RAaEY0psX6jW3M9_LabJnMKY8K_rvGpun9XMmvTMC-ftg130_assertion type Assertion NP448174.RAaEY0psX6jW3M9_LabJnMKY8K_rvGpun9XMmvTMC-ftg130_head.
- NP448174.RAaEY0psX6jW3M9_LabJnMKY8K_rvGpun9XMmvTMC-ftg130_assertion description "[The methylation patterns of the genes p16(INK4a) (p16), tissue inhibitor of metalloproteinase 3 (TIMP3), p15(INK4b) (p15), E-cadherin (ECAD), death-associated protein kinase (DAPK), p73, RAS-association domain family 1A (RASSF1A), p14, O(6)-methylguanine DNA methyltransferase (MGMT), and retinoid acid receptor beta2 (RARbeta) were determined in patients with monoclonal gammopathy of undetermined significance (MGUS; n = 29), smoldering multiple myeloma (SMM; n = 5), multiple myeloma (MM; n = 113), or plasma cell leukemia (PCL; n = 7) by methylation-specific polymerase chain reaction analysis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP448174.RAaEY0psX6jW3M9_LabJnMKY8K_rvGpun9XMmvTMC-ftg130_provenance.
- NP448174.RAaEY0psX6jW3M9_LabJnMKY8K_rvGpun9XMmvTMC-ftg130_assertion evidence source_evidence_literature NP448174.RAaEY0psX6jW3M9_LabJnMKY8K_rvGpun9XMmvTMC-ftg130_provenance.
- NP448174.RAaEY0psX6jW3M9_LabJnMKY8K_rvGpun9XMmvTMC-ftg130_assertion SIO_000772 15197802 NP448174.RAaEY0psX6jW3M9_LabJnMKY8K_rvGpun9XMmvTMC-ftg130_provenance.
- NP448174.RAaEY0psX6jW3M9_LabJnMKY8K_rvGpun9XMmvTMC-ftg130_assertion wasDerivedFrom befree-2016 NP448174.RAaEY0psX6jW3M9_LabJnMKY8K_rvGpun9XMmvTMC-ftg130_provenance.
- NP448174.RAaEY0psX6jW3M9_LabJnMKY8K_rvGpun9XMmvTMC-ftg130_assertion wasGeneratedBy ECO_0000203 NP448174.RAaEY0psX6jW3M9_LabJnMKY8K_rvGpun9XMmvTMC-ftg130_provenance.